Blum Holdings (Blum Holdings) Risk Assessment

View and export this data going back to 2011. Start your Free Trial

What is Blum Holdings Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Blum Holdings is: High Risk: High uncertainty.

Competitive Comparison of Blum Holdings's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Blum Holdings's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Blum Holdings's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Blum Holdings's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Blum Holdings's Risk Assessment falls into.

Blum Holdings (OTCPK:BLMH) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Blum Holdings Risk Assessment Related Terms

Thank you for viewing the detailed overview of Blum Holdings's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Blum Holdings (Blum Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Blum Holdings Inc (OTCPK:BLMH) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

N/A

Address

3242 South Halladay Street, Suite 202, Santa Ana, CA, USA, 92705

Website

https://www.unrivaledbrands.com

Blum Holdings Inc formerly Unrivaled Brands Inc is a vertically integrated cannabis multi-state operator having a cannabis brand spanning consumer products, cultivation, distribution, and retail. Its brands include Korova, Sticks, and Cabana, among others. It operates leading dispensaries throughout the state as well as several leading company-owned brands including Korova, known for its high potency products across multiple product categories.

Executives

Patty Chan	officer: CHIEF FINANCIAL OFFICER	11516 DOWNEY AVE, DOWNEY CA 90241
Oren Schauble	officer: President	3242 S HALLADAY ST., SUITE 202, SANTA ANA CA 92705
Dallas Imbimbo	director	1800 NEWPORT CIRCLE, SANTA ANA CA 92705
Eric Baum	director	866 BERKSHIRE DRIVE, WESTBURY NY 11590
Tiffany N. Davis	director	11852 MANHATTAN CT., RANCHO CUCAMONGA CA 91730
Michael Nahass	director	2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Derek Peterson	director, officer: President and CEO	2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Alan David Gladstone	other: Former Director of Issuer	P.O BOX 9699, NEWPORT BEACH CA 92658
Uri Kenig	officer: Chief Operating Officer	2040 MAIN ST., SUITE 225, IRVINE CA 92614
Ira E. Ritter	director	C/O RITTER PHARMACEUTICALS INC., 1801 CENTURY PARK EAST, SUITE 1820, LOS ANGELES CA 90096
Nicholas Kovacevich	director	2618 SAN MIGUEL DRIVE, #480, NEWPORT BEACH CA 92660
Knuettel Ii Francis	director	205 NEWBURY ST, SUITE 204, FRAMINGHAM MA 01701
Jeffrey Robert Batliner	officer: Chief Financial Officer	2040 MAIN STREET, SUITE 225, IRVINE CA 92614
Megan Jimenez	officer: Chief Financial Officer	2040 MAIN ST., SUITE 225, IRVINE CA 92614
Matthew Morgan	director, officer: Chief Executive Officer	2040 MAIN STREET, SUITE 225, IRVINE CA 92614